Trials / Active Not Recruiting
Active Not RecruitingNCT03122522
A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
A Phase II Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will help determine whether 2 doses of the combination (ipilimumab + nivolumab) is sufficient for patients with early benefit compared to the usual way of trying to give 4 doses. If patients do not show early benefit after 2 doses, patients will be able to continue with additional ipilimumab + nivolumab, even beyond the standard 4 doses if felt in the best interest of the patient.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ipilimumab | ipilimumab 3mg/kg |
| DRUG | nivolumab | nivolumab 1mg/kg |
Timeline
- Start date
- 2017-04-17
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2017-04-20
- Last updated
- 2025-06-25
Locations
14 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03122522. Inclusion in this directory is not an endorsement.